Peijia Medical Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 5/6

Peijia Medical şirketinin toplam hissedar öz sermayesi CN¥2.2B ve toplam borcu CN¥248.4M olup, bu da borç-öz sermaye oranını 11.4% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla CN¥2.6B ve CN¥432.7M dir.

Anahtar bilgiler

11.4%

Borç/özkaynak oranı

CN¥248.40m

Borç

Faiz karşılama oranı	n/a
Nakit	CN¥929.70m
Eşitlik	CN¥2.18b
Toplam yükümlülükler	CN¥432.72m
Toplam varlıklar	CN¥2.61b

Son finansal sağlık güncellemeleri

Güncelleme yok

Recent updates

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: 4WO 'nin kısa vadeli varlıkları ( CN¥1.2B ) kısa vadeli yükümlülüklerini ( CN¥174.4M ) aşıyor.

Uzun Vadeli Yükümlülükler: 4WO şirketinin kısa vadeli varlıkları ( CN¥1.2B ) uzun vadeli yükümlülüklerini ( CN¥258.3M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: 4WO şirketinin toplam borcundan daha fazla nakiti var.

Borcun Azaltılması: 4WO şirketinin 5 yıl önce negatif özkaynağı vardı, ancak şu anda pozitif ve dolayısıyla iyileşme kaydetti.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: 4WO şirketinin mevcut serbest nakit akışına göre 3 yıldan fazla bir süre için yeterli nakit pistine sahip olduğu belirtiliyor.

Tahmini Nakit Akışı: 4WO tarihsel oranlara göre serbest nakit akışı büyümeye veya küçülmeye devam ederse yeterli nakit pistine sahip olup olmadığını belirlemek için yeterli veri yok.

Peijia Medical Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 5/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Recent updates

Peijia Medical Limited Announces Resignation of Yu Zhiyun as Non-Executive Director and A Member of the Board's Remuneration Committee

First half 2024 earnings released: CN¥0.10 loss per share (vs CN¥0.31 loss in 1H 2023)

Less than half of directors are independent

Peijia Medical Limited, Annual General Meeting, Sep 30, 2024

Peijia Medical Limited to Report First Half, 2024 Results on Aug 23, 2024

Peijia Medical Limited to Report Fiscal Year 2023 Results on Jun 15, 2024

Peijia Medical Limited to Report Fiscal Year 2023 Results on Mar 28, 2024

Peijia Medical Announces Successful Completion of Patient Enrollment for Pivotal TaurusTrio Transcatheter Aortic Regurgitation Clinical Trial

First half 2023 earnings released: CN¥0.31 loss per share (vs CN¥0.14 loss in 1H 2022)

Less than half of directors are independent

Forecast to breakeven in 2025

First half 2023 earnings released: CN¥0.31 loss per share (vs CN¥0.14 loss in 1H 2022)

New major risk - Share price stability

Peijia Medical Limited to Report First Half, 2023 Results on Aug 31, 2023

Peijia Medical Limited Announces First Patient in Multi-Center Registration Clinical Trial of Taurustrio™? Transcatheter Aortic Valve Replacement System in China

Peijia Medical Limited Provides Unaudited Revenue Guidance for the Period from January 1, 2023 to June 30, 2023

New minor risk - Profitability

Peijia Medical Limited Receives Approval from the National Medical Products Administration of the PRC for the Registration Application of DCwireTM Micro Guidewire

New minor risk - Share price stability

Executive Director & Company Secretary recently sold €362k worth of stock

Forecast to breakeven in 2025

Peijia Medical Limited Announces First Patient Enrollment in the Multi-Center Registration Clinical Trial of Geminione Transcatheter Edge-To-Edge Repair System in China

Peijia Medical Limited Announces in Partnership with inQB8 Medical Technologies, LLC Successfully Completed the First Patient Implant in the First-In-Man Clinical Trial of the MonarQ Transcatheter Tricuspid Valve Replacement System in the World

Less than half of directors are independent

Peijia Medical Limited Announces First Patient Implant in Multi-Center Registrationclinical Trial of Peijia Highlife Transcatheter Mitralvalve Replacement System in China

Less than half of directors are independent

First half 2022 earnings released: CN¥0.14 loss per share (vs CN¥0.27 loss in 1H 2021)

Peijia Medical Limited to Report First Half, 2022 Results on Aug 19, 2022

Forecast to breakeven in 2024

Peijia Medical Limited Announces Executive Changes

Peijia Medical Limited Receives NMPA Approval for Registration Application of Fluxcap Balloon Guide Catheter

Peijia Medical Limited Receives the Approval from the National Medical Products Administration of the PRC for the Registration Application of Tethys AS Aspiration Catheter

Peijia Medical Limited, Annual General Meeting, Jun 10, 2022

Full year 2021 earnings released: CN¥0.87 loss per share (vs CN¥4.43 loss in FY 2020)

Less than half of directors are independent

Full year 2021 earnings released: CN¥0.86 loss per share (vs CN¥4.43 loss in FY 2020)

Peijia Medical Limited to Report Fiscal Year 2021 Results on Mar 31, 2022

Peijia Medical Limited Receives the Approval from the National Medical Products Administration for Syphonet® Stent Retriever

Peijia Medical Limited Announces First Patient Implant in Research Clinical Trial of Peijia's Highlife Trans-Septal Mitral Valve Replacement System in China

Peijia Medical Announces First Patient Implant in the Clinical Trial of Its Third-Generation Transcatheter Aortic Valve System TaurusNXT

Peijia Medical Limited Announces First Patient Implant in Clinical Trial of TaurusNXT

First half 2021 earnings released: CN¥0.27 loss per share (vs CN¥8.68 loss in 1H 2020)

Peijia Medical Limited Receives the Approval from the National Medical Products Administration of the PRC of the Registration Application for TaurusElite

Full year 2020 earnings released: CN¥4.43 loss per share (vs CN¥2.33 loss in FY 2019)

Full year 2020 earnings released: CN¥4.43 loss per share (vs CN¥2.26 loss in FY 2019)

Peijia Medical Limited to Report Fiscal Year 2020 Results on Mar 29, 2021

Peijia Medical Limited Announces Patient Enrollment for the Clinical Trial Ofshenyi Stent Retriever

New 90-day high: €3.20

New 90-day low: €2.34

New 90-day low: €2.60

Peijia Medical Limited Announces Completion of Patient Enrollment for the Clinical Trial of Tauruselite

Peijia Medical Limited to Report First Half, 2020 Results on Aug 28, 2020

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Nakit Pist Analizi

Sağlıklı şirketleri keşfedin